Overview

Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer

Status:
Active, not recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

National, multi-center, open-label,randomized, 2-arm phase III superiority trial, comparing neoadjuvant chemotherapy (CT) with mFolfirinox followed by preoperative chemoradiotherapy (CRT), versus preoperative CRT in patients with locally advanced rectal cancer.

Phase:

Phase 3

Details

Lead Sponsor:

UNICANCER

Treatments:

Capecitabine
Leucovorin